You are on page 1of 61

Pharmacoepidemiology

NG ICRI Pharmacoepidemiology

Outline of presentation
Definitions The importance of pharmacoepidemiology Studies on drug use Studies on drug effects Signal generation Risk quantification Hypothesis testing Problem solving Applications of pharmacoepidemiology
NG ICRI Pharmacoepidemiology

Definitions
Epidemiology-Study of distribution and determinants of disease in populations
Clinical epidemiology:How to critically evaluate medical literature and how to apply principles of epidemiology to clinical medicine
NG ICRI Pharmacoepidemiology

Pharmacoepidemiology: Definition - 1
Pharmacoepidemiology is the study of
Use of drugs Effect of drugs in large numbers of subjects.

NG ICRI Pharmacoepidemiology

Pharmacoepidemiology Definition 2

Application of the principles of epidemiology to drug use and drug effect in large numbers patients

NG ICRI Pharmacoepidemiology

Evolution of Pharmacoepidemiology as a science


1961 Thalidomide disaster Case reports of limb malformations in offspring of women. Treated with thalidomide Development of systems for Adverse Drug Reactions Monitoring.

Development of the science of Pharmacoepidemiology.

NG ICRI Pharmacoepidemiology

The importance of pharmacoepidemiology- the problem of ADRs


Account for 5% of all hospital admissions. Occur in 10-20% of hospital inpatients. Cause death in 0.1% of medical and 0.01% of surgical inpatients. Adversely effect patients quality of life.

Cause patients to lose confidence in their doctors.


Increase costs of patients care.
NG ICRI Pharmacoepidemiology

The importance of pharmacoepidemiology- the inadequacies of clinical trials For the investigation of certain drug events, models are not possible e.g. pregnancy. RCTs are often inadequate to answer questions on safety.

NG ICRI Pharmacoepidemiology

Aims of Pharmacoepidemiological studies

Signal generation
Risk quantification Hypothesis testing

NG ICRI Pharmacoepidemiology

Studies on drug use

NG ICRI Pharmacoepidemiology

Drug utilization studies


WHO definition: The marketing, distribution, prescription and use of drugs in a society with the resultant medical, social and economic consequences Quantitative or Qualitative (DUR or drug utilization reviews) DURs focus on specific drugs or class of drugs (4th generation cephalosporins, aminoglycosides)
NG ICRI Pharmacoepidemiology

The concepts of DDD and PDD


The defined daily dose (DDD) is the estimated average maintenance dose per day of a drug when used for its major indication (e.g aspirin)

Expressed as DDDs/1000 population In hospitals, DDDs/100 bed days, adjusted for occupancy
NG ICRI Pharmacoepidemiology

Prescribed daily dose -PDD


The prescribed daily dose or PDD is the average daily dose of a drug that has actually been prescribed Calculated from a representative sample of prescriptions

NG ICRI Pharmacoepidemiology

The need for drug utilization studies


Indication of pattern of use of drugs Early signals of irrational use of drugs

Allows comparisons between regions, countries


Interventions to improve drugs use Continuous quality improvement
NG ICRI Pharmacoepidemiology

Study of drug effects

NG ICRI Pharmacoepidemiology

Aims of Pharmacoepidemiological studies?


Signal generation
Risk quantification Hypothesis testing

NG ICRI Pharmacoepidemiology

What is a signal?
Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually more than one report is required to generate a signal depending upon the seriousness of the event and quality of the information.

NG ICRI Pharmacoepidemiology

Rawlins and Thompson classification -1991


Type A Predictable (Augmented) Dose-dependent Related to the drugs pharmacological properties. Diarrhea with antibiotic use. Type B Bizarre, unpredictable. Dose-independent (idiosyncratic). Unrelated

Hypersensitivity with penicillin.

NG ICRI Pharmacoepidemiology

Methods of signal generation

NG ICRI Pharmacoepidemiology

Spontaneous reporting - 1
A system by which practicing clinicians are encouraged to report any and all adverse events with a drug Reports complied at the National Centre Reports from National Centers are then sent to the Uppsala Monitoring Centre.

NG ICRI Pharmacoepidemiology

Spontaneous reporting:- Advantages


Early warning signals
Relatively inexpensive Do not interfere with clinical practice

NG ICRI Pharmacoepidemiology

Spontaneous reporting: Disadvantages


Information inadequate, incomplete, not verifiable Cause- effect difficult to establish Voluntary, thus under reporting Incidence and prevalence difficult to calculate
NG ICRI Pharmacoepidemiology

Prescription Event monitoring - 1


Used for both signal generation and risk quantification

Used to study large cohorts of drugs


5000 18,000 prescriptions from prescribers studied

Information:
All adverse events Death from any cause Hospitalization Fetal abnormalities Changes in laboratory values

Advantages: Calculation of incidence


NG ICRI Pharmacoepidemiology

Prescription event monitoring when?


New chemical entity
Predicted widespread use Identified but unquantified risks

NG ICRI Pharmacoepidemiology

Post-marketing surveillance
Carried out by the pharmaceutical industry A single cohort of 5000-10,000 patients studied

Follow up- months/years Data submitted to regulatory authorities

NG ICRI Pharmacoepidemiology

Record linkage
Monitoring drug use and effect via database research Databases provide accessible information on thousands of patients Each patient in the database has a unique identifier Examples of information- hospitalization, infections developed, death, birth defects, lab investigations, physician services Databases can also be linked Disadvantages: Accuracy of data, missing data, lack of data Advantages: Speed
NG ICRI Pharmacoepidemiology

Methods of Risk Quantification &


Hypothesis testing
NG ICRI Pharmacoepidemiology

What is risk?

The probability of developing an outcome, regardless of severity.

NG ICRI Pharmacoepidemiology

What is a hypothesis ?
A hypothesis is a supposition based on observation or reflection. Cigarette smoking causes lung cancer.

Use of O.C pills causes hypertension and thromboembolic phenomenon.


Epidemiological studies allow you to accept or reject a hypothesis.

NG ICRI Pharmacoepidemiology

Why measure risk postmarketing?


Risk quantification often requires large sample sizes Rule of 3 An AE of 1/3000 will require 9000 subjects to be studied Pre marketing studies usually pick up Type A adverse events (dose dependent)
NG ICRI Pharmacoepidemiology

Risk versus exposure


Single group risk [ cases/ total exposure], does not account for baseline risk.
Risk is always calculated against an another group- unexposed or an experimental exposure

NG ICRI Pharmacoepidemiology

Classification of risk - CIOMS


Very common 1 in 10 exposures
Common Uncommon Rare Very rare < 1 in 10 1 in 100 exposures < 1 in 100 1 in 1000 exposures < 1: 1000 1:10,000 exposures > 1 in 10,000 exposures

NG ICRI Pharmacoepidemiology

Measurement of risk
Absolute risk (AR) Absolute risk reduction (ARR) Relative risk (RR) Relative risk reduction (RRR) Odds ratio (OR) Number needed to treat (NNT)
NG ICRI Pharmacoepidemiology

Problem - 1
In a randomized trial, investigators compared mortality rates in patients with bleeding oesophageal varices treated either by endoscopic ligation or endoscopic sclerotherapy. After a mean follow up of 10 months, 18/64 pts treated with ligation died, 29/65 pts treated with sclerotherapy died.
NG ICRI Pharmacoepidemiology

(1) Absolute risk (AR)


Simplest measure of association Absolute risk of dying in the ligation group is 18/64 or 28% Absolute risk of dying in the sclerotherapy group is 29/65 or 45%
NG ICRI Pharmacoepidemiology

Measurement of risk
Absolute risk (AR) Absolute risk reduction (ARR) Relative risk (RR) Relative risk reduction (RRR) Odds ratio (OR) Number needed to treat (NNT)
NG ICRI Pharmacoepidemiology

(2) Absolute risk reduction (ARR)


Establishes a relation between the two absolute risks Also called as Risk difference (RD) Tells us what proportion of pts are spared the outcome if they receive the experimental therapy (rather than conventional therapy) ARR = 0.445-0.281 = 0.165 = 16.5%
NG ICRI Pharmacoepidemiology

Measurement of risk
Absolute risk (AR) Absolute risk reduction (ARR) Relative risk (RR) Relative risk reduction (RRR) Odds ratio (OR) Number needed to treat (NNT)

NG ICRI Pharmacoepidemiology

(3) The concept of relative risk


RR or risk ratio Defined as the ratio of the risk rate in the exposed population versus unexposed or control versus experimental population

NG ICRI Pharmacoepidemiology

Contingency table/ 2x2 table


An Did not develop Total outcome an outcome Exposed to drug/test a b a+b

Not exposed to c drug/control


RR = a = P1 a+b

d
c = P2 c+d

c+d
P1 P2

NG ICRI Pharmacoepidemiology

P1= 0.446 P2= 0.281 P1/P2 = 0. 63 Thus the risk of death in subjects is 2/3rds that with ligation

Or Subjects receiving sclerotherapy were 1.58 times or one and a half times as likely to die as compared to ligation treated subjects
NG ICRI Pharmacoepidemiology

Measurement of risk
Absolute risk (AR) Absolute risk reduction (ARR) Relative risk (RR) Relative risk reduction (RRR) Odds ratio (OR) Number needed to treat (NNT)
NG ICRI Pharmacoepidemiology

(4) Relative Risk Reduction- RRR


Another measure of assessing effectiveness of treatment What is the proportion of baseline risk that is removed by the experimental therapy ARR / Baseline risk

NG ICRI Pharmacoepidemiology

Relative risk reduction (RRR)


ARR = 0.446 - 0.281 Baseline risk = 0.446 (sclerotherapy group)

RRR = 0.165/0.446 = 0.369 Or ligation decreases the risk of death by 37%


NG ICRI Pharmacoepidemiology

Measurement of risk
Absolute risk (AR) Absolute risk reduction (ARR) Relative risk (RR) Relative risk reduction (RRR) Odds ratio (OR) Number needed to treat (NNT)
NG ICRI Pharmacoepidemiology

(5 ) Odds Ratio

Measures the strength of association between an exposure and outcome

NG ICRI Pharmacoepidemiology

Calculation of odds ratio


Odds in the exposed/odds in the unexposed Odds in the exposed: a/a+b = a b/a+b b Odds in the unexposed:c/c+d = d/c+d
NG ICRI Pharmacoepidemiology

c d

Contingency table/ 2x2 table


An outcome Did not develop Total an outcome

Exposed to drug/test Not exposed to drug/control OR =

a+b

c+d

ad/bc
NG ICRI Pharmacoepidemiology

Calculation of odds ratio


Death No Death Total

Exposed to ligation

18 a

46 b

64 a+b

Exposed to sclerotherapy

29 c

36 d

65 c+d

NG ICRI Pharmacoepidemiology

OR ad/bc

Odds Ratio
Odds of dying in the ligation group is 0.39

Odds of dying in the sclerotherapy group is 0.80


Odds ratio = 0.39/0.80 = 0.48 Inference: Pts treated with ligation have half as likely to die as compared to sclerotherapy

Or, 0.8/0.39, pts treated with sclerotherapy as twice as likely to die as compared to ligation treated subjects
NG ICRI Pharmacoepidemiology

Measurement of risk
Absolute risk (AR) Absolute risk reduction (ARR) Relative risk (RR) Relative risk reduction (RRR) Odds ratio (OR) Number needed to treat (NNT)
NG ICRI Pharmacoepidemiology

(6) Number needed to treat


Another way to express the impact of the new treatment

Allows comparison between treatments


NNT = 1/ARR For every 17 pts treated with ligation, 1 pt will be saved

For 100 pts, 28 pts will die with ligation


For 100 pts, 44.6 pts will die with sclerotherapy
NG ICRI Pharmacoepidemiology

Case control and cohort studies


Case control

Cohort

Proceeds from effect to cause.


Starts with the disease.

Proceeds from cause to effect.


Starts with the risk factor.

Fewer subjects. Larger number of subjects. Quicker results.

Longer follow up.


Relative inexpensive.
NG ICRI Pharmacoepidemiology

Expensive.

Levels of Evidence - 1
Level 1- RCTs, direct comparisons of drugs within the same class, rather than with placebos, for effect on important treatment outcomes

Level 2: 1) RCTs, direct comparisons of drugs within the same class, but on validated surrogate outcomes or 2) Comparisons of active agents with placebos on clinically important outcomes or validated surrogate outcomes
NG ICRI Pharmacoepidemiology

Levels of evidence- 2
Level 3: Placebo controlled trials where outcomes are restricted to unvalidated surrogate markers

Level 4: Non randomized studies (case control, cohort studies)

NG ICRI Pharmacoepidemiology

Applications of Pharmacoepidemiology
Estimation/quantitation of risk Patient counseling

Formulation of public health/policy decisions


Formulation of therapeutic guidelines and discovery of new indications Pharmacoeconomic decision making
NG ICRI Pharmacoepidemiology

Estimation of risks of drug use


The most common application
Use of case-control and cohort studies E.g., Clozapine and agranulocytosis and neutropenia (1:5000 versus 1:200)
NG ICRI Pharmacoepidemiology

Formulation of public-health policy decisions

Is the risk associated with the drugs too high?


Does the labeling need to be changed?

Is there too much of inappropriate prescribing?


NG ICRI Pharmacoepidemiology

Patient counseling
Termination of pregnancy versus continuation of pregnancy when the risk of malformation is low/high

NG ICRI Pharmacoepidemiology

Formulation of therapeutic decision making

Effectiveness and safety of drugs used in groups of people not included in Phase III trials (elderly, pediatrics)
E.g, Use of ciprofloxacin for typhoid fever in children

NG ICRI Pharmacoepidemiology

Summary
Application of principles of epidemiology to the study of the use and effects of drugs in large numbers of patients Deals with signal generation, risk quantification and hypothesis generation Applications in risk quantification, patient counseling, therapeutic, regulatory and economic decision making

NG ICRI Pharmacoepidemiology

You might also like